SCHEMBL1626353

SCHEMBL1626353

O=C1CCC2CCCC12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16691801 1.00
SCHEMBL6903135 0.95 CA1 (0.37)
SCHEMBL7703871 0.95 CA1 (0.37)
SCHEMBL7703873 0.95 CA1 (0.37)
SCHEMBL7706418 0.92 KMT2A (0.39)
SCHEMBL4740702 0.90 CA1 (0.37)
SCHEMBL29107476 0.87 CA1 (0.46)
SCHEMBL9695672 0.87 CA1 (0.46)
SCHEMBL120444 0.84 CA1 (0.42)
SCHEMBL12333841 0.84 CA1 (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5200530-A Carried out in presence of cerium (III) salts SCHERING AKTIENGESELLSCHAFT (DE) 1993-04-06 US claimed
EP-0268548-B1 REDUCTION OF KETONIC CARBACYCLIN INTERMEDIATES SCHERING AKTIENGESELLSCHAFT (DE) 1991-08-21 EP claimed
CN-115108962-B Method for continuously synthesizing azabicyclo compound 上海巽田科技股份有限公司 2024-03-19 CN disclosed
CN-115160210-B Method for synthesizing heterobicyclic compounds 上海巽田科技股份有限公司 2023-10-24 CN disclosed
US-20230331652-A1 TRANS-CYCLOOCTENES WITH HIGH REACTIVITY AND FAVORABLE PHYSIOCHEMICAL PROPERTIES UNIVERSITY OF DELAWARE (US) 2023-10-19 US disclosed
US-20230331652-A1 TRANS-CYCLOOCTENES WITH HIGH REACTIVITY AND FAVORABLE PHYSIOCHEMICAL PROPERTIES UNIVERSITY OF DELAWARE (US) 2023-10-19 US disclosed
US-20230161249-A1 ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE FILM, PATTERN FORMING METHOD, METHOD FOR MANUFACTURING ELECTRONIC DEVICE, AND COMPOUND FUJIFILM CORPORATION (JP) 2023-05-25 US disclosed
US-20230161249-A1 ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE RESIN COMPOSITION, ACTINIC RAY-SENSITIVE OR RADIATION-SENSITIVE FILM, PATTERN FORMING METHOD, METHOD FOR MANUFACTURING ELECTRONIC DEVICE, AND COMPOUND FUJIFILM CORPORATION (JP) 2023-05-25 US disclosed
US-20230082167-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC (US) 2023-03-16 US disclosed
US-20180291029-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC. (US) 2018-10-11 US disclosed
US-9828373-B2 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2017-11-28 US disclosed
US-5200530-A Carried out in presence of cerium (III) salts SCHERING AKTIENGESELLSCHAFT (DE) 1993-04-06 US disclosed
EP-0487673-A1 NEW XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) 1992-06-03 EP disclosed
WO-1992000297-A1 NEW XANTHINE DERIVATIVES BOEHRINGER INGELHEIM KG (DE) 1992-01-09 WO disclosed
EP-0107733-B1 CYCLOALIPHATIC PHARMACEUTICAL COMPOUNDS CBD CORPORATION (US) 1988-10-19 EP disclosed
EP-0268548-A2 Reduction of ketonic carbacyclin intermediates SCHERING AKTIENGESELLSCHAFT (DE) 1988-05-25 EP disclosed
WO-1988003527-A1 IMPROVED KETO-REDUCTION OF CARBACYCLINE INTERMEDIATES SCHERING AKTIENGESELLSCHAFT (DE) 1988-05-19 WO disclosed
EP-0107693-A4 2,3,4-TRINOR-1,5-INTER-M-PHENYLENE-PROSTACYCLIN-I2 ANALOGUES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. CHINOIN GYOGYSZER ES VEGYESZET (HU) 1984-09-17 EP disclosed
EP-0107693-A1 2,3,4-TRINOR-1,5-INTER-M-PHENYLENE-PROSTACYCLIN-I2 ANALOGUES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. CHINOIN GYOGYSZER ES VEGYESZET (HU) 1984-05-09 EP disclosed
WO-1983004021-A1 2,3,4-TRINOR-1,5-INTER-M-PHENYLENE-PROSTACYCLINE-I2 ANALOGUES, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME Chinoin Gyógyszer és Vegyészeti Termékek Gyára Rt. (HU) 1983-11-24 WO disclosed